Appl. No.: 10/785,577 Patent
Art Unit: 1632 1958416,00005

Reply to Notice dated 12/10/2009

Reply to Notice dated 12/10/2009

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-16 (CANCELED)

17. (CURRENTLY AMENDED) A tumor cell composition consisting of comprising:

an—isolated primary tumor cells modified to express [[a]] immune modulators consisting essentially of B7-2 protein and at least one additional immune modulator <u>GM-CSF</u>, wherein said isolated primary tumor cells expressing—B7-2 and at least one additional immune modulator has have been irradiated.

18-50. (CANCELED)

51. (CURRENTLY AMENDED) The tumor cell composition according to claim 17, wherein said tumor cell composition is prepared by a process comprising:

infecting primary tumor cells with a recombinant retrovirus vector encoding both immune modulators consisting essentially of B7-2 and an additional immune modulator-GM-CSE;

selecting the infected primary tumor cells for expression of B7-2 and the additional immune modulator_GM-CSF; and

irradiating said selected primary tumor cells expressing [[B7.2]] B7-2 and at least one additional immune modulator GM-CSF.

52. (CURRENTLY AMENDED) A tumor cell composition comprising [[an]] isolated autologous primary tumor cells transfected to express immune modulators consisting essentially of B7-2 pretein and GM-CSF, wherein said isolated autologous primary tumor cells expressing B7-2 and GM-CSF has have been irradiated.